15th April 2024
06:00

Fusion Antibodies - Contract to develop a bespoke OptiPhage library

2nd April 2024
13:34

Fusion Antibodies - Block admission six monthly return

28th March 2024
17:00

Fusion Antibodies - Total Voting Rights

11th March 2024
15:04

Fusion Antibodies - Holding(s) in Company

11th March 2024
09:10

Fusion Antibodies - Holding(s) in Company

8th March 2024
15:09

Fusion Antibodies - Holding(s) in Company

5th March 2024
10:40

Fusion Antibodies - Result of General Meeting and Total Voting Rights

29th February 2024
17:00

Fusion Antibodies - Total Voting Rights

27th February 2024
07:00

Fusion Antibodies - First purchase order under MSA

14th February 2024
07:15

Fusion Antibodies - Grant of options and issue of shares to directors

14th February 2024
07:00

Fusion Antibodies - Placing to raise £1,375,000

6th February 2024
07:00

Fusion Antibodies - Follow-on project award and R&D update

1st February 2024
07:00

Fusion Antibodies - HMRC R&D tax credit

4th December 2023
12:26

Fusion Antibodies - Director/PDMR Shareholding

4th December 2023
07:00

Fusion Antibodies - Half-year Report

28th November 2023
07:00

Fusion Antibodies - OptiMAL collaboration agreement

Fusion Antibodies Plc (FAB.L) Share Price & News

Bid

-

-

-

Ask

High
-
OPEN
-
VOL
-
MKT CAP
-M

LOW
-
CLOSE
-
SHARES IN ISSUE
59.45M

Fusion Antibodies Plc Company Profile

Fusion Antibodies is a CRO that offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development.

Watchlist